{ "schemaVersion": 2, "eyebrow": "Preventive Medicine", "title": "Breast Cancer Screening", "summary": "For asymptomatic average-risk patients, mammography remains the core screening test. The principal U.S. decision is interval selection—biennial screening from age 40 versus annual strategies—after confirming risk status, avoiding unproven supplemental imaging, and individualizing cessation by health status and willingness to undergo evaluation and treatment.", "seoDescription": "Evidence-based breast cancer screening for average-risk patients: mammography age, interval, stopping decisions, risk assessment, and imaging limits.", "clinicalQuestion": "How should clinicians select mammography timing, interval, and cessation for asymptomatic patients at average breast cancer risk?", "specialty": "Preventive Medicine", "audience": "U.S. physicians and medical trainees", "tags": [ "breast cancer screening", "screening mammography", "average-risk women", "breast cancer risk assessment", "breast MRI", "breast density" ], "keyTakeaways": [ "Confirm average-risk status before applying routine screening schedules; pathogenic variants, prior chest radiation at young ages, high-risk lesions, substantial family history, and prior breast cancer require risk-directed surveillance rather than average-risk pathways. [16][17][23]", "Current U.S. recommendations converge on beginning routine mammography at age 40, but interval recommendations differ: USPSTF supports biennial screening, whereas ACR recommends annual screening. [17][20][23]", "For average-risk patients, MRI and ultrasound are not routine substitutes for mammography; supplemental imaging may increase cancer detection but also recalls and benign biopsies. [23][24]", "After age 75, screening should be individualized by health status, life expectancy, and whether the patient would accept diagnostic evaluation and treatment if cancer is found. [15][16][23]" ], "sections": [ { "id": "clinical-approach", "eyebrow": "Point-of-care approach", "heading": "Start with risk classification, then choose a mammography interval", "intro": "Routine screening applies only after excluding symptoms and identifying elevated-risk features.", "paragraphs": [ "A screening mammogram is appropriate for an asymptomatic patient at average risk. A new mass, nipple discharge, focal breast symptoms, skin change, or an abnormal screening result requires diagnostic evaluation rather than continuation of a screening pathway. [16][23]", "Periodically update personal and family history, prior breast pathology, chest radiation exposure, mammographic density, and known germline findings. Important elevated-risk features include pathogenic breast-cancer susceptibility variants, prior therapeutic chest radiation at young ages, atypical ductal or lobular hyperplasia or lobular carcinoma in situ, personal history of breast cancer, and a calculated lifetime risk of at least 20%. These patients merit breast-specialty and, when indicated, genetics referral for individualized surveillance. [16][17][23]", "For average-risk patients, the practical U.S. choice is generally annual versus biennial mammography beginning at age 40. Annual strategies favor maximal detection but increase false-positive recalls and benign biopsies; biennial strategies reduce these harms with some loss of incremental benefit. [15][16][20][24]" ], "bullets": [ "Document the intended pathway: average-risk screening, high-risk surveillance, or diagnostic workup.", "Use a validated risk model when family history or prior biopsy findings suggest risk beyond that captured by age alone; no single office-based approach is standardized. [15][16]", "Do not use a low risk-model estimate to deny age-appropriate mammography; use risk assessment to identify patients needing more intensive screening or genetic evaluation. [16]" ], "subsections": [], "table": { "caption": "Average-risk mammography interval decisions in U.S. practice. [17][20][23]", "columns": [ "Clinical decision", "Evidence-informed action", "Tradeoff to discuss" ], "rows": [ [ "Initiation", "Offer or initiate routine mammography at age 40 for asymptomatic average-risk patients. [17][20][23]", "Earlier screening captures cancers in the 40s but produces more false-positive evaluations than at older ages. [15][16]" ], [ "Interval", "Biennial mammography is the USPSTF approach; annual mammography is recommended by ACR. [17][20]", "Annual screening may improve detection but increases callbacks, benign biopsies, and screening burden. [15][16]" ], [ "Stopping", "Individualize beyond age 75 according to health status, estimated longevity, and willingness to pursue downstream testing and treatment. [15][16][23]", "Evidence is limited in patients older than 74 years; age alone should not determine cessation. [15][16]" ] ] } }, { "id": "average-risk-screening", "eyebrow": "Eligibility and interval", "heading": "Who should receive routine mammography and when", "intro": "Mammography is the primary screening modality for average-risk patients.", "paragraphs": [ "The USPSTF 2024 recommendation supports biennial screening mammography for women aged 40 through 74 years. [23] ACOG’s focused update likewise revised routine mammography initiation to age 40. [20] ACR recommends annual screening beginning at age 40. [17] Thus, start age is now largely aligned, while screening interval remains the main guideline-level disagreement.", "The choice between annual and biennial screening should be explicit rather than accidental. In prior modeling summarized by ACOG, annual screening from ages 50 to 74 was associated with two additional lives saved per 1,000 women compared with biennial screening, but also 82 additional biopsies and six additional overdiagnosed tumors per 1,000 women. [16] These estimates support shared decision-making when local systems, patient preferences, and risk modifiers do not clearly favor one interval.", "Continue mammography while the patient has sufficient health and anticipated longevity to benefit from early detection and would accept evaluation and treatment of a screen-detected cancer. ACOG recommends continuing at least through age 75, then individualizing based on health status and longevity; ACR similarly emphasizes health status rather than an age-based cutoff. [15][16]" ], "bullets": [ "For patients aged 40 to 74: offer biennial mammography as the USPSTF schedule; annual screening is a reasonable alternative consistent with ACR guidance. [17][23]", "For patients older than 75: reassess competing mortality, functional status, patient priorities, and whether an abnormal finding would lead to biopsy and treatment. [15][16]", "For patients unable or unwilling to undergo diagnostic workup or treatment, routine screening is unlikely to provide meaningful benefit. [16]" ], "subsections": [], "table": { "caption": "Why interval discussions matter: screening-related harms accumulate with more frequent mammography. [16]", "columns": [ "Outcome over 10 years", "Annual screening", "Biennial screening" ], "rows": [ [ "Cumulative false-positive result", "61% [16]", "42% [16]" ], [ "Cumulative biopsy requirement", "7% [16]", "5% [16]" ] ] } }, { "id": "risk-assessment", "eyebrow": "Risk triage", "heading": "Identify patients who are not average risk", "intro": "Routine schedules should not replace formal risk assessment when history indicates elevated risk.", "paragraphs": [ "Risk assessment should include reproductive history, prior breast biopsy pathology, prior ionizing radiation exposure, breast density, and family history of breast, ovarian, pancreatic, prostate, and other germline mutation-associated cancers, including ages at diagnosis and paternal as well as maternal relatives. [16]", "The Gail/Breast Cancer Risk Assessment Tool is widely used but may underrepresent risk from paternal or second-degree family history, nonbreast hereditary cancers, and some high-risk lesions. BRCAPRO, BOADICEA, IBIS/Tyrer-Cuzick, and Claus are alternative validated tools that may better capture selected patterns. [16]", "ACR recommends risk assessment by age 25, particularly for Black women and women of Ashkenazi Jewish heritage, to identify candidates for earlier and more intensive surveillance. For women with genetics-based risk, calculated lifetime risk of at least 20%, or young-age chest radiation exposure, ACR recommends MRI surveillance beginning at ages 25 to 30 and annual mammography at a risk-dependent age. [17]" ], "bullets": [ "Refer for genetic counseling/testing when personal or family history suggests a hereditary cancer syndrome. [16]", "Consider annual MRI plus mammography for patients meeting high-risk criteria; do not extrapolate this approach to average-risk patients. [17][23]", "Patients with prior breast cancer, atypia, or dense breasts may need individualized supplemental imaging decisions rather than a generic average-risk schedule. [17][23]" ], "subsections": [], "table": { "caption": "Examples of features that move patients outside average-risk screening pathways. [16][17][23]", "columns": [ "Risk feature", "Clinical implication" ], "rows": [ [ "Pathogenic breast cancer susceptibility variant or untested first-degree relative with a known variant", "Earlier risk-directed screening; ACR recommends annual MRI beginning at ages 25 to 30 for genetics-based increased risk. [17]" ], [ "Calculated lifetime risk at least 20%", "Annual MRI surveillance and annual mammography are recommended by ACR. [17]" ], [ "Therapeutic chest radiation at young ages", "Earlier MRI and mammographic surveillance; ACR identifies this group as higher than average risk. [17]" ], [ "Atypical hyperplasia, LCIS, or personal history of breast cancer", "Specialty risk assessment and individualized surveillance rather than routine average-risk screening alone. [16][17][23]" ] ] } }, { "id": "modality-selection", "eyebrow": "Imaging selection", "heading": "Use mammography as the screening foundation; do not routinely add ultrasound or MRI", "intro": "More imaging detects more findings, not necessarily better patient outcomes.", "paragraphs": [ "Mammography is the primary screening modality across major guidelines for average-risk populations. Screening mammography is used for asymptomatic patients; abnormal findings require diagnostic mammography and targeted evaluation. [16][22][23]", "Digital breast tomosynthesis may be used with screening mammography and is preferred by some organizations, but mammography remains the foundation. [16][23] In patients with dense breasts, mammographic sensitivity is reduced, but the USPSTF found insufficient evidence to assess supplemental ultrasound or MRI after a negative mammogram. [23]", "MRI, contrast-enhanced mammography, molecular breast imaging, and ultrasound can increase cancer detection in selected populations but increase recalls and benign biopsies. For average-risk patients, they should not be presented as universal replacements for mammography. Reserve supplemental imaging for risk-informed decisions, local expertise, and shared discussion of downstream harms. [17][23]" ], "bullets": [ "Do not use thermography as a screening substitute; it is not included in standard screening guidelines. [23]", "Ultrasound is principally a diagnostic adjunct for a clinical or mammographic abnormality; it has limited value as a primary screening method because of poor specificity and inability to identify microcalcifications. [23]", "Use MRI principally for elevated-risk surveillance, not as default screening for average-risk patients. [17][23]" ], "subsections": [], "table": { "caption": "Role of breast imaging modalities in average-risk screening. [16][17][23]", "columns": [ "Modality", "Role in average-risk care", "Key limitation" ], "rows": [ [ "Mammography or tomosynthesis", "Primary screening modality. [16][17][23]", "False-positive recalls, benign biopsies, overdiagnosis, and lower sensitivity in dense breasts. [16][23]" ], [ "Ultrasound", "Diagnostic adjunct; not universal supplemental screening. [16][23]", "Operator dependence, limited specificity, and increased false-positive findings. [23]" ], [ "Contrast-enhanced breast MRI", "Not routine for average-risk screening. [17][23]", "More sensitive but less specific, requires contrast, and increases downstream testing. [17][23]" ], [ "Thermography", "Not recommended for routine screening. [23]", "Not included in standard screening guidelines. [23]" ] ] } }, { "id": "counseling-and-follow-up", "eyebrow": "Communication", "heading": "Counsel about screening harms and ensure follow-up of abnormal results", "intro": "A screening recommendation is incomplete without a plan for abnormal findings.", "paragraphs": [ "Discuss benefits alongside false positives, recall imaging, benign biopsy, overdiagnosis, overtreatment, discomfort, anxiety, and cumulative radiation exposure. Harms are more frequent with earlier and more intensive screening. [16] ACOG reported 10-year cumulative false-positive rates of 61% with annual and 42% with biennial screening, illustrating why interval preferences should be elicited. [16]", "Counsel breast self-awareness rather than structured self-examination. Patients should report a new mass, focal pain, nipple discharge, retraction, or skin change promptly; these symptoms require clinical and diagnostic evaluation, not routine screening scheduling. [15][16]", "Clinical breast examination is not a substitute for mammography. Guidance differs: ACOG permits it as an informed shared-decision option, whereas ACP states it is not useful as a screening approach for average-risk women. [8][15][16]" ], "bullets": [ "Before ordering: verify that the patient is asymptomatic, has no high-risk feature requiring a different pathway, and would pursue evaluation of an abnormal result.", "After an abnormal screen: arrange diagnostic imaging and tissue sampling when indicated; do not defer management to the next routine screening interval. [16][23]", "Use a tracking system for abnormal results and missed diagnostic follow-up, particularly where access barriers may delay care. [22]" ], "subsections": [], "table": { "caption": "Counseling points that change screening decisions. [15][16][23]", "columns": [ "Topic", "Practical message" ], "rows": [ [ "Annual versus biennial screening", "Annual screening prioritizes more frequent detection; biennial screening reduces cumulative false-positive evaluations and biopsies. [16]" ], [ "Breast symptoms", "Symptoms trigger diagnostic evaluation regardless of age or most recent screening result. [16][23]" ], [ "Stopping screening", "Stop or defer when serious comorbidity, limited longevity, or patient preference means diagnosis and treatment would not be pursued. [16]" ], [ "Dense breasts", "Dense tissue both modestly raises risk and reduces mammographic sensitivity, but evidence remains insufficient for universal supplemental MRI or ultrasound after a negative mammogram. [16][23]" ] ] } }, { "id": "areas-of-disagreement", "eyebrow": "Evidence limits", "heading": "Where recommendations differ", "intro": "Disagreement reflects different weighting of mortality benefit versus cumulative screening harms.", "paragraphs": [ "U.S. organizations now largely agree on beginning mammography at age 40, but disagree on screening interval. USPSTF supports biennial screening through age 74, while ACR supports annual screening from age 40. [17][23] ACOG supports screening every 1 or 2 years through shared decision-making. [16]", "The evidence base is least certain for patients older than 75 years, universal supplemental imaging in dense breasts, and the outcome benefit of clinical breast examination in average-risk populations. These are settings for individualized decisions rather than reflexive testing. [15][16][23]", "Mammography screening reduces breast cancer mortality, but harms are real and vary by age, interval, density, prior imaging availability, and patient preferences. The clinical task is to make these tradeoffs explicit while ensuring that high-risk patients are not misclassified as average risk. [15][16][17]" ], "bullets": [], "subsections": [], "table": { "caption": "", "columns": [], "rows": [] } } ], "faq": [ { "question": "What is the recommended mammography interval for an average-risk 40-year-old patient?", "answer": "Biennial mammography from age 40 through 74 is the USPSTF approach; ACR recommends annual mammography from age 40. ACOG supports annual or biennial screening after discussing benefits and harms. [16][17][23]" }, { "question": "Should dense breasts automatically prompt screening MRI or ultrasound?", "answer": "No. Dense breasts reduce mammographic sensitivity and are associated with increased risk, but the USPSTF found insufficient evidence to recommend universal supplemental ultrasound or MRI after a negative mammogram. Consider overall risk, access, and downstream false-positive consequences. [16][23]" }, { "question": "When should screening mammography stop?", "answer": "Do not stop solely because of age. Beyond age 75, individualize according to health status, anticipated longevity, and whether the patient would accept diagnostic evaluation and treatment if cancer is found. [15][16][23]" }, { "question": "Is clinical breast examination recommended for screening average-risk patients?", "answer": "It is not a substitute for mammography. ACP considers it not useful for average-risk screening; ACOG permits it as an optional shared-decision intervention while acknowledging uncertain incremental benefit and false-positive consequences. [8][15][16]" }, { "question": "Which patients should be referred for high-risk breast screening assessment?", "answer": "Refer patients with pathogenic variants or concerning family history, young-age therapeutic chest radiation, atypical hyperplasia or LCIS, personal history of breast cancer, or calculated lifetime risk of at least 20%. These patients may need annual MRI and earlier mammography. [16][17][23]" } ], "references": [ { "number": 1, "title": "[PDF] FEMARA (letrozole) tablets - accessdata.fda.gov", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020726s027lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov" }, { "number": 2, "title": "The Voice of the Patient - FDA.report", "detail": "www.fda.gov", "url": "https://www.fda.gov/media/93924/download", "authors": "www.fda.gov", "host": "www.fda.gov" }, { "number": 3, "title": "CENTER FOR DRUG EVALUATION AND RESEARCH", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021660Orig1s026.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov" }, { "number": 4, "title": "FDA Executive Summary General Issues Panel Meeting on ...", "detail": "www.fda.gov", "url": "https://www.fda.gov/media/188185/download", "authors": "www.fda.gov", "host": "www.fda.gov" }, { "number": 5, "title": "Lynparza - accessdata.fda.gov", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov" }, { "number": 6, "title": "Revtorpyk - accessdata.fda.gov", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/219908Orig1s000ltr.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov" }, { "number": 7, "title": "MCGP-112923-Executive Summary", "detail": "www.fda.gov", "url": "https://www.fda.gov/media/174141/download", "authors": "www.fda.gov", "host": "www.fda.gov" }, { "number": 8, "title": "New ACP Guidance Statement: Breast Cancer Screening in Average-Risk Women | NEJM Clinician", "detail": "clinician.nejm.org", "url": "https://clinician.nejm.org/new-acp-guidance-statement-breast-cancer-screening-average-risk-women-nejm-jw.NA48893", "authors": "clinician.nejm.org", "host": "clinician.nejm.org" }, { "number": 9, "title": "Screening for Breast Cancer in Asymptomatic, Average ...", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/10.7326/ANNALS-25-05116", "authors": "www.acpjournals.org", "host": "www.acpjournals.org" }, { "number": 10, "title": "Screening for Breast Cancer in Average-Risk Women", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/10.7326/M18-2147", "authors": "www.acpjournals.org", "host": "www.acpjournals.org" }, { "number": 11, "title": "Breast Cancer Screening and Diagnosis: A Synopsis of the ...", "detail": "annals.org", "url": "https://annals.org/aim/fullarticle/2756145/breast-cancer-", "authors": "annals.org", "host": "annals.org" }, { "number": 12, "title": "Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry | npj Breast Cancer", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41523-021-00306-9", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 13, "title": "Understanding Recommendations From Various Breast ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S1555415524003143", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 14, "title": "Comparing the Various Breast Cancer Screening Guidelines - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S1555415519300066", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 15, "title": "Practice Bulletin No. 179 Summary: Breast Cancer... : Obstetrics & Gynecology", "detail": "journals.lww.com", "url": "https://journals.lww.com/greenjournal/fulltext/10.1097/aog.0000000000002151~practice-bulletin-no-179-summary-breast-cancer-risk", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 16, "title": "Practice Bulletin Number 179: Breast Cancer Risk... : Obstetrics & Gynecology", "detail": "journals.lww.com", "url": "https://journals.lww.com/greenjournal/fulltext/10.1097/aog.0000000000002158~practice-bulletin-number-179-breast-cancer-risk-assessment", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 17, "title": "Breast Cancer Screening for Women at Higher-Than-Average Risk: Updated Recommendations From the ACR", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S1546144023003344", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 18, "title": "Global guidelines for breast cancer screening: A systematic ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0960977622000765", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 19, "title": "Breast Cancer Screening in the Precision Medicine Era: Risk ...", "detail": "academic.oup.com", "url": "https://academic.oup.com/jnci/article/109/5/djw290/2938659", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 20, "title": "Age to Initiate Routine Breast Cancer Screening : Obstetrics & Gynecology", "detail": "journals.lww.com", "url": "https://journals.lww.com/greenjournal/fulltext/10.1097/aog.0000000000005757~age-to-initiate-routine-breast-cancer-screening-acog", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 21, "title": "Imaging", "detail": "academic.oup.com", "url": "https://academic.oup.com/book/62502/chapter/558966095/chapter-pdf/67553337/med-9780198911296-chapter-12.pdf", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 22, "title": "Global guidelines for breast cancer screening: A systematic review☆", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9142711", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 23, "title": "Breast Cancer Screening in the Average-Risk Patient - NCBI", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK556050", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 24, "title": "Screening for Breast Cancer: A Comparative Review of Guidelines", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11204612", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "[PDF] FEMARA (letrozole) tablets - accessdata.fda.gov", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020726s027lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov", "snippet": "nt Treatment of Early Brea st Cancer 1.2 Extended Adju vant Treatment of Early Breast Ca ncer 1.3 First a nd Second-Line Treatment of Adva nced Brea st Cancer 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dose 2.2 Use in Adju vant Treatment of Early Br ea st Ca ncer 2.3 Use in Extended Adjuvant Treatm", "score": 0.31992877 }, { "number": 2, "title": "The Voice of the Patient - FDA.report", "detail": "www.fda.gov", "url": "https://www.fda.gov/media/93924/download", "authors": "www.fda.gov", "host": "www.fda.gov", "snippet": "life. Current Treatment Options - The standard of care for breast cancer depends on the type and stage of cancer, a patient’s overall health, age, and medical issues, and personal preferences. - Treatments for breast cancer include some combination of surgery, chemotherapy, radiation, hormone, and/o", "score": 0.26743823 }, { "number": 3, "title": "CENTER FOR DRUG EVALUATION AND RESEARCH", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021660Orig1s026.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov", "snippet": "5.1, 6.1) DO NOT SUBSTITUTE FOR OR WITH OTHER PACLITAXEL FORMULATIONS -------------------------- RECENT MAJOR CHANGES ----------------------------------------------------- INDICATIONS AND USAGE ---------------------------ABRAXANE is a microtubule inhibitor indicated for the treatment of breast cance", "score": 0.21408322 }, { "number": 4, "title": "FDA Executive Summary General Issues Panel Meeting on ...", "detail": "www.fda.gov", "url": "https://www.fda.gov/media/188185/download", "authors": "www.fda.gov", "host": "www.fda.gov", "snippet": "cancer death in women, and the lifetime risk of a woman in the US developing breast cancer is approximately 13% . Due to this risk, screening mammograms scheduled on a regular basis are recommended for all women at average risk. Because study participants for clinical studies involving dermal filler", "score": 0.14673436 }, { "number": 5, "title": "Lynparza - accessdata.fda.gov", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov", "snippet": "X 4 Reference ID: 4610866 This label may not be the latest approved by FDA. For current labeling information, please visit gBRCAm HER2-negative metastatic breast cancer gBRCA1m, gBRCA2m X First-line maintenance treatment of germline BRCA-mutated metastatic pancreatic adenocarcinoma gBRCA1m, gBRCA2m", "score": 0.13245869 }, { "number": 6, "title": "Revtorpyk - accessdata.fda.gov", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/219908Orig1s000ltr.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov", "snippet": "that a drug continues to comply with compendial standards, application holders may work directly with USP-NF to revise official USP monographs. More information on the USP-NF is available on USP’s website6. 4 5 6 Reference ID: 5833843 NDA 219908 Page 7 U.S. Food and Drug Administration Silver Spr", "score": 0.13145196 }, { "number": 7, "title": "MCGP-112923-Executive Summary", "detail": "www.fda.gov", "url": "https://www.fda.gov/media/174141/download", "authors": "www.fda.gov", "host": "www.fda.gov", "snippet": "A positive result may indicate the presence of [cancer] and should be followed by diagnostic [test name]. [test name] is indicated to screen adults of either sex, 50 years or older, who are at typical average risk for [cancer]. [test name] is not a replacement for diagnostic [test name] or surveilla", "score": 0.12192625 }, { "number": 8, "title": "New ACP Guidance Statement: Breast Cancer Screening in Average-Risk Women | NEJM Clinician", "detail": "clinician.nejm.org", "url": "https://clinician.nejm.org/new-acp-guidance-statement-breast-cancer-screening-average-risk-women-nejm-jw.NA48893", "authors": "clinician.nejm.org", "host": "clinician.nejm.org", "snippet": "The ACP committee noted that, in general, the magnitude of reduction in breast cancer mortality associated with mammography screening is small, a point it believes most guidelines did not emphasize. The guidance statement also points out that most guidelines did not demonstrate any reduction among w", "score": 0.3556859 }, { "number": 9, "title": "Screening for Breast Cancer in Asymptomatic, Average ...", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/10.7326/ANNALS-25-05116", "authors": "www.acpjournals.org", "host": "www.acpjournals.org", "snippet": "by A Qaseem · 2026 · Cited by 3 — In asymptomatic, average-risk females aged 40 to 49 years, clinicians should discuss the female's risk of breast cancer, values and preferences,", "score": 0.4391465 }, { "number": 10, "title": "Screening for Breast Cancer in Average-Risk Women", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/10.7326/M18-2147", "authors": "www.acpjournals.org", "host": "www.acpjournals.org", "snippet": "by A Qaseem · 2019 · Cited by 271 — In women aged 50 to 74 years receiving annual mammography, modeling studies suggested small reductions in breast cancer mortality (2 deaths per 1000 women) and", "score": 0.40882006 }, { "number": 11, "title": "Breast Cancer Screening and Diagnosis: A Synopsis of the ...", "detail": "annals.org", "url": "https://annals.org/aim/fullarticle/2756145/breast-cancer-", "authors": "annals.org", "host": "annals.org", "snippet": "by HJ Schünemann · 2020 · Cited by 350 — This synopsis of the European Breast Guidelines discusses 15 key recommendations related to organized programs for breast cancer screening in women aged 40", "score": 0.29013586 }, { "number": 12, "title": "Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry | npj Breast Cancer", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41523-021-00306-9", "authors": "www.nature.com", "host": "www.nature.com", "snippet": ".\"). FDA approval of tamoxifen and raloxifene in women with a 5-year BCRAT risk of 1.67% or greater has not led to widespread prescription and uptake of risk-reducing therapy13.\"),21.\"). [...] A primary care physician’s recommendation often plays a significant role in a patient’s decision-making; ri", "score": 0.23472267 }, { "number": 13, "title": "Understanding Recommendations From Various Breast ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S1555415524003143", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "by MJ Cadet · 2025 · Cited by 2 — In this report, we highlight the recommendations of breast cancer screening guidelines for average-risk female patients. Section snippets. Screening Guidelines.", "score": 0.5012457 }, { "number": 14, "title": "Comparing the Various Breast Cancer Screening Guidelines - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S1555415519300066", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "# Feature Article Comparing the Various Breast Cancer Screening Guidelines. Nurse practitioners need to understand the screening guideline recommendations for breast cancer. Assess their patients’ risk factors for breast cancer using validated risk assessment tools. Implement shared decision making ", "score": 0.41037872 }, { "number": 15, "title": "Practice Bulletin No. 179 Summary: Breast Cancer... : Obstetrics & Gynecology", "detail": "journals.lww.com", "url": "https://journals.lww.com/greenjournal/fulltext/10.1097/aog.0000000000002151~practice-bulletin-no-179-summary-breast-cancer-risk", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Obstetrics & Gynecology 75th Anniversary\n\nCrossmark: Check for updates\n\n# Practice Bulletin No. 179 Summary: Breast Cancer Risk Assessment and Screening in Average-Risk Women\n\nBreast cancer is the most commonly diagnosed cancer in women in the United States and the second leading cause of cancer dea", "score": 0.58123237 }, { "number": 16, "title": "Practice Bulletin Number 179: Breast Cancer Risk... : Obstetrics & Gynecology", "detail": "journals.lww.com", "url": "https://journals.lww.com/greenjournal/fulltext/10.1097/aog.0000000000002158~practice-bulletin-number-179-breast-cancer-risk-assessment", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Obstetrics & Gynecology 75th Anniversary\n\nCrossmark: Check for updates\n\n# Practice Bulletin Number 179: Breast Cancer Risk Assessment and Screening in Average-Risk Women\n\nBreast cancer is the most commonly diagnosed cancer in women in the United States and the second leading cause of cancer death in", "score": 0.5809471 }, { "number": 17, "title": "Breast Cancer Screening for Women at Higher-Than-Average Risk: Updated Recommendations From the ACR", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S1546144023003344", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE a", "score": 0.5798055 }, { "number": 18, "title": "Global guidelines for breast cancer screening: A systematic ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0960977622000765", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "by W Ren · 2022 · Cited by 470 — Most guidelines recommend annual or biennial mammographic screening between 40 and 74 years for the average-risk populations and annual MAM or annual MRI", "score": 0.5614318 }, { "number": 19, "title": "Breast Cancer Screening in the Precision Medicine Era: Risk ...", "detail": "academic.oup.com", "url": "https://academic.oup.com/jnci/article/109/5/djw290/2938659", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "by Y Shieh · 2017 · Cited by 310 — For women age 40 to 49 years, screening is recommended when their five-year risk equals or exceeds that of the average woman age 50 years.", "score": 0.31295812 }, { "number": 20, "title": "Age to Initiate Routine Breast Cancer Screening : Obstetrics & Gynecology", "detail": "journals.lww.com", "url": "https://journals.lww.com/greenjournal/fulltext/10.1097/aog.0000000000005757~age-to-initiate-routine-breast-cancer-screening-acog", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Obstetrics & Gynecology 75th Anniversary\n\nCrossmark: Check for updates\n\n# Age to Initiate Routine Breast Cancer Screening\n\n## ACOG Clinical Practice Update\n\nThis Clinical Practice Update provides revised guidance on the age to start routine breast cancer screening with mammography. This document is ", "score": 0.22456558 }, { "number": 21, "title": "Imaging", "detail": "academic.oup.com", "url": "https://academic.oup.com/book/62502/chapter/558966095/chapter-pdf/67553337/med-9780198911296-chapter-12.pdf", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "Mammography in combination with breast ultrasonography versus mam- mography for breast cancer screening in women at average risk. Cochrane Database Syst Rev.", "score": 0.2064941 }, { "number": 22, "title": "Global guidelines for breast cancer screening: A systematic review☆", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9142711", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "for Breast Cancer in Average-Risk Women: A Guidance Statement From the American College of Physicians12007The United States 2019NCCNBreast Cancer Screening and Diagnosis, Version 1.201991998 2003 2006 2010 2013 2015 2016 2017 2018The United States 2017ACRACR Appropriateness Criteria® Breast Cancer S", "score": 0.8559598 }, { "number": 23, "title": "Breast Cancer Screening in the Average-Risk Patient - NCBI", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK556050", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "Clinical breast examinations are recommended every 1 to 3 years for women aged 25 to 39 and annually for women aged 40 or older. Screening typically continues until the patient’s life expectancy is less than age 10, with the decision to discontinue based on individual health status and overall life ", "score": 0.82492816 }, { "number": 24, "title": "Screening for Breast Cancer: A Comparative Review of Guidelines", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11204612", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "## , the U.S. Preventive Services Task Force (USPSTF), the American Cancer Society (ACS), the National Comprehensive Cancer Network (NCCN), the American College of Obstetricians and Gynecologists (ACOG), the American Society of Breast Surgeons (ASBrS), the American College of Radiology (ACR), the Ta", "score": 0.8005209 } ], "publishedAt": "2026-08-21T00:13:51.596677Z", "updatedAt": "2026-08-21T00:13:51.596677Z", "readingMinutes": 6, "slug": "breast-cancer-screening" }